Copy number variation (CNV) could predict response to EGFR TKI therapy in patients with advanced NSCLC.27,28 However, the impact of EGFR amplification on the efficacy of dual therapy with an anti-angiogenic agent and EGFR TKI remains undefined and was explored in this study. This evidence concerns the gene EGFR and non-small cell lung carcinoma.